Q32 Bio Inc. (QTTB) Financial Statements (2024 and earlier)

Company Profile

Business Address 830 WINTER STREET
WALTHAM, MA 02451
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments82,653175,026155,873217,431262,388214,737
Cash and cash equivalents39,26633,986108,382217,43153,77438,220
Short-term investments43,387141,04047,491 208,614176,517
Prepaid expense      
Other current assets      
Other undisclosed current assets1,2615,98936,0362,1334,1896,948
Total current assets:83,914181,015191,909219,564266,577221,685
Noncurrent Assets
Operating lease, right-of-use asset65020,56315,6075,897 
Property, plant and equipment 1,0782,25237,00242,71635,637
Long-term investments and receivables  25,800    
Long-term investments  25,800    
Restricted cash and investments      
Other noncurrent assets      
Other undisclosed noncurrent assets 141,9531,2741,2741,772
Total noncurrent assets:65047,45519,81244,17343,99037,409
TOTAL ASSETS:84,564228,470211,721263,737310,567259,094
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities10,25510,41211,57912,1197,95719,601
Employee-related liabilities7,8056,9024,5513,370
Accounts payable3,2341,1442,3664,7222,60815,732
Accrued liabilities7,0219,2681,408495798499
Deferred revenue  1,1563,2085,632809
Debt      
Deferred compensation liability  800    
Deferred rent credit     1,313977
Other undisclosed current liabilities1,31810,2082,4394,9072,2954,855
Total current liabilities:11,57322,57617,22622,65812,37425,433
Noncurrent Liabilities
Long-term debt and lease obligation  23,68812,941  
Long-term debt, excluding current maturities      
Liabilities, other than long-term debt 27,9161,15632,14339,6869,470
Deferred revenue   1,15632,14330,142
Deferred rent credit     9,5449,470
Other liabilities      
Operating lease, liability 27,91623,68812,941 
Other undisclosed noncurrent liabilities      29,474
Total noncurrent liabilities: 27,91624,84445,08439,68638,944
Total liabilities:11,57350,49242,07067,74252,06064,377
Equity
Equity, attributable to parent72,991177,978169,651195,995258,507194,717
Common stock666543
Additional paid in capital615,088607,513593,784524,358457,994292,187
Accumulated other comprehensive income (loss)(5)(404)(7) 183(77)
Accumulated deficit(542,098)(429,137)(424,132)(328,368)(199,674)(97,396)
Total equity:72,991177,978169,651195,995258,507194,717
TOTAL LIABILITIES AND EQUITY:84,564228,470211,721263,737310,567259,094

Income Statement (P&L) ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues2,3123,20833,9712,7021,6663,684
Amortization of lease incentives6,320   
Sublease income 2,3121,979861913 
Gross profit:2,3123,20833,9712,7021,6663,684
Operating expenses(102,585)(136,489)(129,920)(132,965)(111,609)(65,248)
Other undisclosed operating loss (1,156)     
Operating loss:(101,429)(133,281)(95,949)(130,263)(109,943)(61,564)
Nonoperating income14,349134,4793703,1386,0274,349
Investment income, nonoperating   1851,569  
Other nonoperating income14,349134,4791851,5696,0274,349
Income (loss) from continuing operations before equity method investments, income taxes:(87,080)1,198(95,579)(127,125)(103,916)(57,215)
Loss from equity method investments      
Income (loss) from continuing operations before income taxes:(87,080)1,198(95,579)(127,125)(103,916)(57,215)
Income tax expense  (715)    
Income (loss) from continuing operations:(87,080)483(95,579)(127,125)(103,916)(57,215)
Loss before gain (loss) on sale of properties:(95,579)(127,125)(103,916)(57,215)
Other undisclosed net loss(25,881)(5,488)(185)(1,569)  
Net loss:(112,961)(5,005)(95,764)(128,694)(103,916)(57,215)
Other undisclosed net loss attributable to parent      
Net loss available to common stockholders, basic:(112,961)(5,005)(95,764)(128,694)(103,916)(57,215)
Other undisclosed net loss available to common stockholders, diluted      
Net loss available to common stockholders, diluted:(112,961)(5,005)(95,764)(128,694)(103,916)(57,215)

Comprehensive Income ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(112,961)(5,005)(95,764)(128,694)(103,916)(57,215)
Comprehensive loss:(112,961)(5,005)(95,764)(128,694)(103,916)(57,215)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent399(397)(7)(183)260(4)
Comprehensive loss, net of tax, attributable to parent:(112,562)(5,402)(95,771)(128,877)(103,656)(57,219)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: